Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) had its target price lowered by Morgan Stanley from $100.00 to $95.00 in a report published on Friday, Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company's stock.
Several other brokerages also recently issued reports on RARE. Cowen lowered their price target on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a report on Thursday, November 3rd. Cowen lowered their target price on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a research note on Thursday, November 3rd. HC Wainwright restated a buy rating and set a $82.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 30th. Wedbush restated a neutral rating on shares of Ultragenyx Pharmaceutical in a research note on Thursday, October 13th. Finally, Robert W. Baird upgraded Ultragenyx Pharmaceutical from a neutral rating to an outperform rating and lowered their target price for the company from $63.00 to $50.00 in a research note on Thursday, November 3rd. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $91.69.
Get Ultragenyx Pharmaceutical alerts:Ultragenyx Pharmaceutical Trading Down 3.4 %
Shares of NASDAQ RARE opened at $45.73 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $33.36 and a 12-month high of $85.53. The stock has a fifty day moving average price of $43.04 and a 200 day moving average price of $43.66.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.29) by ($0.14). Ultragenyx Pharmaceutical had a negative net margin of 197.47% and a negative return on equity of 84.14%. The company had revenue of $90.70 million during the quarter, compared to analyst estimates of $98.76 million. On average, equities analysts expect that Ultragenyx Pharmaceutical will post -8.84 earnings per share for the current fiscal year.Insider Transactions at Ultragenyx Pharmaceutical
In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 2,031 shares of the firm's stock in a transaction dated Wednesday, December 21st. The shares were sold at an average price of $43.96, for a total value of $89,282.76. Following the transaction, the chief accounting officer now owns 16,197 shares of the company's stock, valued at $712,020.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company's stock.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
A number of large investors have recently bought and sold shares of the business. Lazard Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 36.6% in the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 240 shares during the last quarter. Chartwell Investment Partners LLC lifted its holdings in Ultragenyx Pharmaceutical by 3.6% in the third quarter. Chartwell Investment Partners LLC now owns 7,623 shares of the biopharmaceutical company's stock worth $316,000 after acquiring an additional 268 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 7.6% during the second quarter. Virtus ETF Advisers LLC now owns 4,895 shares of the biopharmaceutical company's stock valued at $292,000 after buying an additional 345 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Ultragenyx Pharmaceutical by 2.1% during the second quarter. Arizona State Retirement System now owns 17,863 shares of the biopharmaceutical company's stock valued at $1,066,000 after buying an additional 359 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 151.0% during the third quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 361 shares during the last quarter. Institutional investors own 93.17% of the company's stock.
About Ultragenyx Pharmaceutical
(Get Rating)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Featured Stories
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.